You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The increase was drive by revenue growth in Cancer Genetics' discovery services unit, which included the impact of recently acquired CRO VivoPharm.
The firm is selling BioServe to Reprocell as part of Cancer Genetics' transformation and strategic plan to bring itself to profitability.
Near-term, the firm is focused on its cost structure and growing its top line with a view to becoming profitable, according to its interim CEO.
The test is designed to identify a tumor's tissue of origin by assessing 2,000 individual genes and covers 15 common tumor types.
The lawsuits allege the company made false and/or misleading statement and/or failed to disclose information that was pertinent to investors.
The firm is in the midst of evaluating its strategic options and has hired Raymond James to assist in the process, which could include the sale of the firm, it said.
The companies will join their respective technologies into a precision oncology testing and analysis offering.
Quest will also have early access to Thermo Fisher's pipeline of novel platforms and assays to assist with development of Oncomine-branded solutions.
Technologies gained one of their first solid footholds in the clinical care of cancer patients with adoption into the treatment paradigm of lung cancer, while researchers turned their eyes to proving utility in other niches.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.